{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+Dose+Drug+A&page=16", "query": { "intervention": "Low Dose Drug A", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 1207, "total_pages": 121, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+Dose+Drug+A&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+Dose+Drug+A&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T13:04:24.737Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06834347", "title": "A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Rhinosinusitis With Nasal Polyps" ], "interventions": [ { "name": "Itepekimab (SAR440340)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Mometasone furoate nasal spray (MFNS)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 231, "start_date": "2025-02-12", "completion_date": "2027-03-26", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-11-15T13:04:24.737Z", "location_count": 21, "location_summary": "Arcadia, California • Los Angeles, California • Newport Beach, California + 16 more", "locations": [ { "city": "Arcadia", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06834347" }, { "nct_id": "NCT02255565", "title": "Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "ADHD", "Autism" ], "interventions": [ { "name": "Very Low Dose Quillivant XR", "type": "DRUG" }, { "name": "Low Dose Quillivant XR", "type": "DRUG" }, { "name": "Moderate Dose Quillivant XR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seattle Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "5 Years to 16 Years" }, "enrollment_count": 36, "start_date": "2014-09", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2017-08-01", "last_synced_at": "2026-11-15T13:04:24.737Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02255565" }, { "nct_id": "NCT02744092", "title": "Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer", "Venous Thromboembolism", "Deep Vein Thrombosis (DVT)", "Pulmonary Embolism (PE)", "Blood Clot" ], "interventions": [ { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Apixaban", "type": "DRUG" }, { "name": "Edoxaban", "type": "DRUG" }, { "name": "Dabigatran", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Dalteparin", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" }, { "name": "Fondaparinux", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance Foundation Trials, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 811, "start_date": "2016-12-13", "completion_date": "2021-02-22", "has_results": true, "last_update_posted_date": "2023-10-03", "last_synced_at": "2026-11-15T13:04:24.737Z", "location_count": 151, "location_summary": "Chula Vista, California • Fremont, California • Fresno, California + 104 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02744092" }, { "nct_id": "NCT02430818", "title": "Comparing Ketamine and Morphine in the Treatment of Acute Fracture Pain", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Pain", "Fractures" ], "interventions": [ { "name": "ketamine", "type": "DRUG" }, { "name": "morphine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2015-04", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2019-05-22", "last_synced_at": "2026-11-15T13:04:24.737Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02430818" }, { "nct_id": "NCT01951885", "title": "Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Myelogenous Leukemia", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Acute Biphenotypic Leukemia", "Myelodysplastic Syndrome", "Myeloproliferative Neoplasm", "Non-Hodgkin Lymphoma", "Hodgkins Disease", "Chronic Lymphocytic Leukemia", "Multiple Myeloma" ], "interventions": [ { "name": "tacrolimus", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Methotrexate (low dose)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 101, "start_date": "2014-07-07", "completion_date": "2021-08-11", "has_results": true, "last_update_posted_date": "2023-09-11", "last_synced_at": "2026-11-15T13:04:24.737Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01951885" }, { "nct_id": "NCT04408625", "title": "Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Frontotemporal Dementia" ], "interventions": [ { "name": "LY3884963", "type": "BIOLOGICAL" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Optional Sirolimus", "type": "DRUG" }, { "name": "Optional Prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Prevail Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "30 Years to 85 Years" }, "enrollment_count": 35, "start_date": "2020-11-09", "completion_date": "2029-11-30", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-11-15T13:04:24.737Z", "location_count": 4, "location_summary": "Maitland, Florida • Orlando, Florida • Burlington, Massachusetts + 1 more", "locations": [ { "city": "Maitland", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Burlington", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04408625" }, { "nct_id": "NCT01924182", "title": "Intrathecal Morphine Compared to Conventional Medical Management for Pain Control and Opioid-related Side Effects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Pain" ], "interventions": [ { "name": "SynchroMed Infusion System and Intrathecal Morphine Sulfate", "type": "DEVICE" }, { "name": "Conventional Medicine", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "MedtronicNeuro", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2013-10", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-11-15T13:04:24.737Z", "location_count": 6, "location_summary": "Homewood, Alabama • Napa, California • Walnut Creek, California + 3 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Napa", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01924182" }, { "nct_id": "NCT03447782", "title": "Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "New Daily Persistent Headache (NDPH)" ], "interventions": [ { "name": "Naltrexone HCl (Bulk) Powder", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boston Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "10 Years to 17 Years" }, "enrollment_count": 45, "start_date": "2018-07-23", "completion_date": "2020-11-20", "has_results": true, "last_update_posted_date": "2022-05-06", "last_synced_at": "2026-11-15T13:04:24.737Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03447782" }, { "nct_id": "NCT04464070", "title": "Pathways of Eicosanoid Metabolism", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Metabolism of Prostaglandin D2" ], "interventions": [ { "name": "niacin", "type": "DIETARY_SUPPLEMENT" }, { "name": "aspirin", "type": "DRUG" }, { "name": "PGD2", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "OTHER" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2020-08-15", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-11-15T13:04:24.737Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04464070" }, { "nct_id": "NCT04291703", "title": "STOP-T1D Low-Dose (ATG)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Antithymocyte Globulin", "type": "DRUG" }, { "name": "Placebo (for ATG)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "34 Years", "sex": "ALL", "summary": "6 Years to 34 Years" }, "enrollment_count": 2, "start_date": "2023-11-01", "completion_date": "2024-12-17", "has_results": true, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-11-15T13:04:24.737Z", "location_count": 20, "location_summary": "Orange, California • San Francisco, California • Stanford, California + 17 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04291703" } ] }